Current approaches in familial colorectal cancer: A clinical perspective

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 4, 2006, Pages 421-430

  Lynch, Patrick M ^a,b  

^a University of Texas M D Anderson Cancer Center ^*

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoma surveillance; Genetic testing; Hereditary colon cancer

Indexed keywords

ADENOMATOUS POLYP; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; FAMILY HISTORY; GENE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; INCIDENCE; MEDICAL SOCIETY; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MYH GENE; PRACTICE GUIDELINE; PROCTOCOLECTOMY; RECTUM RESECTION; REVIEW; COLON POLYPOSIS; COLORECTAL TUMOR; GENETICS; MASS SCREENING; METHODOLOGY;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; MASS SCREENING;

EID: 33747120331     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0034     Document Type: Review

References (96)

1. Potter JD, McMichael AJ. Diet and cancer of the colon and rectum: a case-control study. J Natl Cancer Inst 1986;76:557-569.
2. Cummings JH, Bingham SA. Diet and the prevention of cancer. BMJ 1998;317:1636-1640.
3. American Cancer Society. Cancer Facts and Figures 2004. Atlanta: American Cancer Society; 2004.
4. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force, 2nd ed. Baltimore: Williams & Wilkins; 1996.
5. Tomeo CA, Colditz GA, Willett WC, et al. Harvard Report on Cancer Prevention. Volume 3: prevention of colon cancer in the United States. Cancer Causes Control 1999;10:167-180.
6. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer. CA Cancer J Clin 2005;55:31-44.
7. Selby JV, Friedman GD, Quesenberry CP Jr, et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-657.
8. Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-1575.
9. Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing fro colorectal neoplasia population screening. Brit J Surg 1997;84:1274-1276.
10. Vernon S. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997;89:1406-1422.
11. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003;349:2191-2200.
12. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005;128:192-206.
13. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
14. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-665.
15. van der Luijt RB, Khan PM, Vasen HF, et al. Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. Hum Mutat 1997;9:7-16.
16. Meuller J, Kantor-Smoler G, Nygren AOH, et al. Identification of genomic deletions of the APC gene in familial adenomatous polyposis by two independent quantitative techniques. Genet Test 2004;8:248-256.
17. Leppert M, Burt R, Hughes JP, et al. Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. N Engl J Med 1990;322:904-908.
18. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993;75:951-957.
19. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 2002;30:227-232.
20. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.
21. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004;127:9-16.
22. Eliason K, Hendrickson BC, Judkins T, et al. The potential for increased clinical sensitivity in genetic testing for polyposis colorectal cancer through the analysis of MYH mutations in North American patients. J Med Genet 2005;42:95-96.
23. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-1453.
24. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1995;5:751-756.
25. Coburn MC, Pricolo VE, DeLuca FG, et al. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995;2:386-391.
26. Desai DC, Neale KF, Talbot IC, et al. Juvenile polyposis. Br J Surg 1995;82:14-17.
27. Jass JR, Williams CB, Bussey HJR, Morson BC. Juvenile polyposis-a precancerous condition. Histopathology 1988;13:619-630.
28. Hemminki A, Markte D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-187.
29. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-1088.
30. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor IA in juvenile polyposis. Nat Genet 2001;28:184-187.
31. Schumacher V, Vogel T, Leube B, et al. STK 11 genotyping and cancer risk in Peutz-Jeghers syndrome. J Med Genet 2005;42:428-435.
32. American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. ASHG statement: professional disclosure of familial genetic information. Am J Hum Genet 1998;62:474-483.
33. Berk T, Cohen Z, Bapat B, et al. Negative genetic test result in familial adenomatous polyposis: clinical screening implications. Dis Colon Rectum 1999;42:307-310; discussion 310-312.
34. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 1991;100:1658-1664.
35. Bülow S, Bülow C, Nielsen TF, et al. Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the Danish Polyposis Register. Scand J Gastroenterol 1995;30:989-993.
36. Church J, Burke C, McGannon E, et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003;46:1175-1181.
37. Heiskanen I, Järvinen HJ: Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Int J Colorectal Dis 1997;12:9-13.
38. Bülow S, Björk J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004;53:381-386.
39. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
40. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
41. Hawk E, Umar A, Viner JL. Colorectal cancer chemoprevention-an overview of the science. Gastroenterology 2004;126:1423-1447.
42. Vasen HF, Offerhaus GJ, den Hartog Jager FC, et al. The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer 1990;46:31-34.
43. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995;64:430-433.
44. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516-520.
45. Lynch HT, Lynch PM, Pester J, et al. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 1981;141:607-611.
46. Suspiro A, Fidalgo P, Cravo M, et al. The Muir-Torre syndrome: a rare variant of hereditary nonpolyposis colorectal cancer associated with hMSH2 mutation. Am J Gastroenterol 1998;93:1572-1574.
47. Kruse R, Rütten A, Lamberti C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998;63:63-70.
48. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-847.
49. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
50. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456.
51. Cao Y, Pieretti M, Marshall J, et al. Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the liter-ature. Am J Gastroenterol 2002;97:1822-1827.
52. Beck NE, Tomlinson IP, Homfray T, et al. Genetic testing is important in families with a history suggestive of hereditary non-polypo-sis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg 1997:84:233-237.
53. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998;339:511-518.
54. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screen-ing for the disease. N Engl J Med 1998;338:1481-1487.
55. Kievit W, de Bruin JH, Adang EM, et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 2004;65:308-316.
56. Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-812.
57. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-1225.
58. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87:1114-1125.
59. Lindblom A, Tannergard P, Werelius B, Nordenskjold M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 1993;5:279-282.
60. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258-261.
61. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-1629.
62. Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-272.
63. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994;371:75-80.
64. Aaltonen LA, Peltomȧki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816.
65. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-1762.
66. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
67. Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology 2003;124:1574-1594.
68. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268.
69. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996;56:4836-4340.
70. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-1048.
71. Rigau V, Sebbagh N, Olschwang S, et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 immunostaining. Arch Pathol Lab Med 2003;127:694-700.
72. de La Chapelle A. Microsatellite instability phenotype of tumors: genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 2002;20:897-899.
73. Jass JR, Stewart SJ, Lane MR. Hereditary non-polyposis colorectal cancer-morphologies, genes and mutations. Mutat Res 1994;310:125-133.
74. Miyakura Y, Sugano K, Konishi F, et al. Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. Gastroenterology 2001;121:1300-1309.
75. Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF, and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-533.
76. Domingo E, Laiho P, Ollkainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41:664.
77. Syngal S, Fox EA, Li C, et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 1999;282:247-253.
78. American Society of Human Genetics. ASHG Statement: Professional disclosure of familial genetic information. Am J Hum Genet 1999;62:474-483.
79. Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2005;23:1902-1910.
80. Wang Y, Friedl W, Lamberti C, et al. Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 2003;103:636-641.
81. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition-update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 2004;20:269-276.
82. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860.
83. Aaltonen LA, Salovaaru R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-1487.
84. Baudhuin LM, Ferber MJ, Winters JL, et al. Characterization of hMLH1 and hMSH2 gene dosage alterations in Lynch syndrome patients. Gastroenterology 2005;129:846-854.
85. Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-1411.
86. Vasen HF, van Ballegooijen M, Buskens E, et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998;2:1632-1637.
87. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
88. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997;277:915-919.
89. Vasen HF, den Hartog Jager FC, Menko FH, et al. Screening for hereditary non-polyposis colorectal cancer: a study of 22 kindreds in The Netherlands. Am J Med 1989;86:278-281.
90. Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut 2002;50:382-386.
91. Kiesslich R, Jung M, DiSario J A, et al. Perspectives of chromo and magnifying endoscopy: how, how much, when, and whom should we stain. Clin Gastro 2004;38:7-13.
92. Halvarsson B, Lindblom A, Johansson L, et al. Loss of mismatch repair protein immunostaining in colorectal adenomas with hereditary nonpolyposis colorectal cancer. Mod Pathol 2005;18:1095-1101.
93. De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 2004;126:42-48.
94. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-1981.
95. Citarda F, Tomaselli G, Capocaccia R, et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001;48:812-815.
96. Ahmad NA, Kochman ML, Long WB, et al. Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc 2002;55:390-396.